Free Trial
Want deep insights into your competitors & competitive landscape? Try Patsnap Eureka!

Top 5 Key Players companies in Hemorrhagic Fevers
by Most Market Reports in the Austria in 2021

The Hemorrhagic Fevers top 5 is Discovery PatSnap’ annual ranking of the top 5 Most Market Reports Hemorrhagic Fevers Key Players in the Austria. Discovery has identified the top key players, startups & unicorns, fast-growings, news entrants in 2021, ranking from differnt perspectives, including patent filing intensity, academic research capability, news media heat. The company list is generated from various data types.

Viral hemorrhagic fevers (VHFs) are a group of illnesses caused by four families of viruses. These include the Ebola and Marburg, Lassa fever, and yellow fever viruses. VHFs have common features: they affect many organs, they damage the blood vessels, and they affect the body's ability to regulate itself. Some VHFs cause mild disease, but some, like Ebola or Marburg, cause severe disease and death.

VHFs are found around the world. Specific diseases are usually limited to areas where the animals that carry them live. For example, Lassa fever is limited to rural areas of West Africa where rats and mice carry the virus.

The risk for travelers is low, but you should avoid visiting areas where there are disease outbreaks. Because there are no effective treatments for some of these viral infections, there is concern about their use in bioterrorism.

Centers for Disease Control and Prevention

#
Company Name
Region
Tech Topics
Total
1
Themis Bioscience GmbH
Biotechnology,Clinical trial,Health care,
...[+2]
market report: 2
2
Marinomed Biotech AG
Product design,Medicine,Health care,
...[+2]
market report: 1
3
EVER Neuro Pharma GmbH
Medicine,Health care,Pharmaceutical manufacturing,
...[+2]
market report: 1
4
Kwizda Pharma GmbH
Good manufacturing practice,Pharmaceutical manufacturing
market report: 1
5
Merck Sharp & Dohme GmbH
Medicine,Luteinizing hormone,Levothyroxine,
...[+2]
market report: 1
Page generation time: May 18 2025